Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 225538

AbstractMaterial and MethodsResultsDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2011 | Month : November | Volume : 5 | Issue : 7 | Page : 1402 - 1405 Full Version

Is Trioxide Arsenic Useful for the Treatment of Acute Myeloid Non-promylocytic Leukaemia?


Published: November 1, 2011 | DOI: https://doi.org/10.7860/JCDR/2011/.1673
Iraj Asvadi Kermani, Farahnaz Ghahremanfard, Zohreh Sanaat, Roya Dolatkhah

1. Professor of Haematology and Medical Oncology , Haematology and Oncology Research Center, Tabriz University of Medical Sciences 2. Assistant Professor of Haematology and Medical Oncology, Haematology and Oncology Research Center, Tabriz University of Medical Sciences 3. Assistant Professor of Haematology and Medical Oncology, Haematology and Oncology Research Center, Tabriz University of Medical Sciences 4. MD, Haematology and Oncology Research Center, Tabriz University of Medical Sciences

Correspondence Address :
Iraj Asvadi Kermani,
Haematology and Oncology Research Center,
Tabriz University of Medical Sciences
Phone: 0098 411 3361358; Fax: 0098 411 3343844
E-mail: iraj_akermani@hotmail.com; horc_tums@tbzmed.ac.ir

Abstract

Introduction: Acute leukaemia has a severe clinical process and can be rapidly fatal if it is not treated. Despite the modern treatment, many patients die due to the nature of the disease or the treatment side effects. Among the proposed forms of treatment, there is no standard and uniform treatment for those who are not completely remitted or those who had a reactivation of the disease. Therefore, it is emphasis to a newer treatment as a medical emergency. With due attention to the toxicity of the cytotoxic drugs, a series of non-toxic treatment options have been proposed. One of the newer drugs which are used for the treatment of acute leukaemia is Trioxide Arsenic. Because of the appropriate response of acute promylocytic leukaemia (APL) to Trioxide Arsenic and because of its relatively lower side effects, we decided to use it for the treatment of acute myeloid leukaemia (non-promylocytic) (AML) which was resistant to drug therapy.

Aim of the Study: We aimed to assess the complete remission with Trioxide Arsenic in patients with acute myeloid leukaemia (non-promylocytic) who were resistant to therapy and its correlation with the age and duration of the disease from the diagnosis to the treatment.

Material and Method: Patients with acute myeloid leukaemia, who were resistant to the treatment, were enrolled in the study. A complete history was obtained and a complete physical examination was done before the treatment. Peripheral blood smear and bone marrow examinations were done during the therapy, every two weeks. The treatment with Trioxide Arsenic was started. The complete remission was confirmed according to the standard definition of remission for acute myelogenic leukaemia.

Results: In our study, out of 7 patients, one had complete remission, one had partial remission and 4 patients had no remissions. One patient abandoned the study. There was no significant correlation between the times of the treatment, from the beginning of the disease until the beginning of the treatment. Also, there was no significant correlation between the age of the patients and their response to Trioxide Arsenic. The median survival for the patients was 3.66 months and all the patients who responded and did not respond to the treatment, died.

Conclusion: According to the median survival of the patients, it seems that Trioxide Arsenic alone is not a good drug for the treatment of acute myeloid non-promylocytic leukaemia. However, with regards to one complete remission and one partial remission and the lesser side effects of Trioxide Arsenic, we recommend the use of this drug in clinical trials and in the lab cultures of the leukaemic cells.

Keywords

Trioxid Arsenic, Promylocytic myeloid leukaemia, Acute non-promylocytic myeloid leukaemia

Introduction:
Acute myeloid leukaemia is an infiltration of haematopoietic neoblastic cells which are derived from myeloid cells in the blood, bone marrow and other tissues of the human body. Acute leukaemia has a rapid clinical course and if it is not treated medically, it can be severely fatal (1). Acute myeloid leukaemia (AML) is usually seen in elderly people. The mean age is 65 years and if it is not treated, the median survival period is less than 3 months (2). Despite innovative treatment, the patients die, either due to the disease or due to the complications of the treatment (3) 60-80% of the younger patients were found to attain a complete remission following the recent, standard, aggressive and maintenance treatment, but however, this percentage is lower in adults (4), (5). The current treatment for AML is the 7+3 regimen which includes Citarabine and Anthracycline. Anyway, this type of therapy does not cure many patients. Relapse was seen in 50% of the patients who were in complete remission. Consequently, despite the treatment, the 2 year survival in the patients with the reactivation of the disease was only 20%. Among the proposed treatments, there is no uniform standard treatment for the patients who have the reactivation of the disease (6),(7),(8).

So, if the patient dose not respond to two consecutive aggressive therapies, the outcome will be poor and furthermore, the treatmentregimen will be more complicated. For this reason, an approach to a newer therapy is a medical emergency.

Due to the toxicity of the cytotoxic drugs, a series of non-toxic treatments are on the way,which include differentiating agents, enzyme inhibitors and monoclonal antibodies (8). One of the new drugs is Trioxide Arsenic. This drug has the ability to cause differentiation and apoptosis in the promylocytic leukaemic cells. Complete remission with this drug was seen in 85% of the patients who were affected by promylocytic leukaemia in its relapse. Recently, this drug has been used to treat other forms of acute promylocytic leukaemia (9),(10),(11). With regards to a complex of these investigations and the relatively lesser side effects of Trioxide Arsenic, we decided to use it for the treatment of acute myeloid leukaemia (non-promyelocytic), which was resistant to the treatment (12).

Material and Methods

For 3 years (from to), the patients with acute myeloid leukaemia who were resistant to the treatment, who were referred to our clinic, were enrolled in an analytical, cross-sectional study. A written consent for the treatment trials was obtained from all the patients. Before the treatment, a complete history was obtaineda(n2d) careful physical examination w(3a)s done. Also, the time which elapsed from the beginning of the disease and the start of the treatment with Trioxide Arsenic was recorded. The CBC count was obtained, staining of the slides with Peroxidase was done and the levels of creatinine, urea, fasting blood sugar, transaminase and electrolytes including Na, K and Mn were evaluated The ECG was also recorded. During the treatment, the bone marrow examination and PBS were done every week. The ECG was checked and the above mentioned laboratory tests were done 3 times a week. The treatment with Trioxide Arsenic was started with a dose of 0.1 mg/ kg daily by IV infusion for 2 hours. During the therapy, if the patients reached complete remission, the treatment would be continued for another week; otherwise, the treatment was continued for up to 56 days. The complete remission was based on the standard characteristics of the complete remission for acute myelogenic leukaemias.

Results

A total of 7 patients with AML and non-APL were referred and treated by Trioxide Arsenic. The demographic and other data of the patients are listed in (Table/Fig 1). One patient (14.3%) discontinued the drug ten days after the beginning of the treatment. One patient (14.3%) had complete remission, but died due to an acute crisis after the treatment. One patient (14.3%) had partial remission (blasts less than 20%), but died due to acute leukaemia. Four patients (57.1%) did not respond to the therapy and all of them died due to the complications of leukaemia. Overall, 6 patientsunderwent the treatment; 1 patient had a partial response,1 had a complete response (both 28.6%) and 4 patients did not respond to the treatment (Table/Fig 2).

The mean time from the diagnosis to the treatment with Trioxide Arsenic was 5.14 ±1.18 months for all the patients, it was 4.75±1.1 months for the patients who did not respond to the treatment and it was 7±4 months for the patients who completely or partially responded to the treatment (Table/Fig 3). This difference was not statistically significant. The mean age of the patients was 52± 1.1 years. The mean age was 52.75±12.67 years for the patients who did not respond to the treatment and it was 49±2 years for the patients who responded completely or partially to the treatment (Table/Fig 3). This difference was not statistically significant. The mean time of the treatment with Trioxide Arsenic was 40± 6.87 days. This period was 39.5±6.88 days for those who did not respond to the treatment and it was 56 days in the patients who responded completely or partially to the treatment [Table/Fig 4]. This difference was not statistically significant.

The median survival time after the start of the treatment was 3.66 months. All the patients died as a result of leukaemia, but not due to the alterations in the laboratory tests which included creatinine, urea, FBS, transaminase, K, Na, Mg which They died due to the side effects of the therapy. We did the CBC count of all patients during the treatment. The patients who had complete or partial remission did not need any therapy for anaemia and thrombocytopaenia. Patients who did not respond to the treatment had CBC changes which were related to leukaemia, which needed treatment. There were no ECG changes in any patients.

Discussion

Over the last few decades, a variety of clinical researches which were conducted worldwide, have demonstrated the efficacy of Trioxide Arsenic for treating relapsed acute promyelocytic leukaemia. Currently, the role of this drug in the front-line therapyis under investigation (13). Recent trials have demonstrated that its addition to the standard treatment regimens could improve the patients’ survival and outcomes and that it might allow a reduction in the cytotoxic effects of the drugs. It has also been revealed that the therapeutic doses of Trioxide Arsenic are well tolerated, with no evidence of long-term toxicity. The adverse events include electrocardiographic abnormalities and mild elevations in the liver enzymes. But, these side effects were found to rarely occur (14).

In our study on 7 patients, one of them was found to have complete remission, one had partial remission and four of them showed no response to the treatment. One patient left the study. There was no statistically significant correlation between the period of the time between the diagnosis and the start of the treatment with Trioxide Arsenic and also between the age of the patients and their response to Trioxide Arsenic.

The mean survival of our patients was 3.66 months, but it was found that if the patients were not treated, their mean survival was less than 3 months. Due to a low sample size, we couldn’t confirm these findings. For a better conclusion on the effect of Trioxide Arsenic on the mean survival; more detailed investigations with more numbers of patients are needed.

In their study, Simrit Parmar et al reported that of 11 patients who were affected by AML and non APL, none of them responded to the treatment with Trioxide Arsenic and that the disease progressed in all patients (15). The mean survival of these patients was 2.25 months as compared to the 3.66 month survival in our patients. The difference between these 2 groups may be the number of patients in both the groups. Our patients were treated with first line treatments and salvage protocols, but in the Simirit Parmar study, the patients were those in whom the disease had relapsed and those who had failed to respond to the first line treatment, those who had secondary AML or whose age was more than 65 years old. Maybe their genetic and racial backgrounds had an influence on their treatment. Although the dose of Trioxide Arsenic in their study was higher than that in our study, no results were obtained. However, to confirm the effect of Trioxide Arsenic in the treatment of AMLand non-APL, a study with a large sample size is needed We concluded that ATO should not be used (at least) alone, for patients with AML and non APL. However, in our study, one case had complete remission after using Trioxide Arsenic alone.

Safak Yuske et al observed that high doses of methyl prednisolone caused the differentiation of the myeloid blast cells into mature granulocytes . If methyl prednisolone was given with ATO, it would also result in the differentiation of the acute myeloid leukaemic cells and thus, these drugs would have a synergic effect (16). In our study, ATO was given alone. With regards to the synergic effect of Trioxide Arsenic and methyl prednisolone, these drugs should be used together in future.

Gail et al studied patients with AML and non-APL, who were over 60 years old. These patients received Trioxide Arsenic plus low dose Citarabine. Out of the 61 patients, 21 attained complete remission (34%). This study concluded that adding ATO to low dose Citarabine was better than using Citarabine alone. So, it seemed that low dose Citarabine and Trioxide Arsenic together had a synergic effect (17). We used ATO alone; out of 7 patients, only one patient (14.3%) had complete remission. Our study has no age limitation, but in Gail et al’s study the patients who were selected were more than 65 years old. Did the age factor in these two studies have an effect on the treatment outcome or not? This is a question that needs to be answered through future studies.

Another study showed that if the catalizator which was used on the leukaemic cells was accompanied by ATO, it would result in a higher mortality rate of the cells in comparison to the use of ATO alone. Also, adding FLT3 inhibitors to the Trioxide Arsenic increased the inhibition of the growth and apoptosis of the myeloid leukaemic cells in comparison to the use of ATO alone. Also, in a study on rats with AML and non APL, it was seen that the inhibition of compensating increased Gluthatione could decrease the resistance to Trioxide Arsenic and that it consequently increased its cytotoxicity effect. In our study, we used ATO alone. Perhaps, if the inhibitors of catalase, FLT3 and compensating increased of glutathione were used accompanied with Trioxide Arsenic; we have better response in our patients. Aquaglyceropurine (AQP) could play a role in the intracellular absorption of Arsenic and so, an increase in the dose of Aquaglyceropurine could increase the cytotoxicity of ATO. The use of ATRA could increase the Aquaglyceropurine 9. Thus, the synergic effect of ATRA and ATO is due to this mechanism. Therefore, the use of ATRA with ATO could increase the expression of Aquaglyceropurine 9 and this could improve our results (18),(19),(20) (21).

Conclusion

Although in our study, one of the 7 patients had complete remission, because of the short mean survival of the patients, it seems that Trioxide Arsenic alone is not a suitable drug for patients with AML and non APL. However, with due attention to this fact that we had one complete remission and one partial remission and also because of the lesser side effects of Trioxide Arsenic, it was not wise to put it off. Therefore, it is necessary that this drug be used in the first phase of the clinical trials and for the cell cultivation of leukaemia samples in the laboratory.

From the investigations which were made on the cell cultivation media, on laboratory animals and in aged patients and in the first phase of the clinical trials, it was seen that the use of a high dose of methyl prednisolone, a low dose of citarabin, inhibitors of catalase, inhibitors of FLT3 and inhibitors of compensating increased of gluthatione resulted in an increased effect of Trioxide Arsenic. Therefore, it recommended that the use of these drugs be accompanied by the use of Trioxide Arsenic, which was assessed in clinical trials and in the laboratory cell cultivation of the leukaemic cells.

Knowledge about the real mechanism of action of Trioxide Arsenic can give us better information about the dose of the drug, the factors which influence the increase and decrease of its action and the factors which have a synergic effect with Trioxide Arsenic. Therefore, there is a need for more studies in this area.

Finding new methods of treatment, especially non toxic drugs for patients with acute myeloid leukaemia, should be considered as a medical emergency and it should be a part of all the research programs.

References

1.
Sheinberg DA, Maslak P, Weiss M. Acute leukemias. In: DeVita Jr. VT, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology 5.7th ed. Lippincott Williams and Wilkins, Philadelphia , PA, 2004, 400.
2.
Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology. American Society of Haematology. Education Program, 2004; 98-117.
3.
Cripe LD. Adult acute leukemia. Current Problems in Cancer (Review) 1997; 21(1):1-64.
4.
Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. British Journal of Haematology, 1992; 81:170–7.
5.
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. For the Cancer and Leukaemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. The New England Journal of Med. 1994; 332:217–23.
6.
Jackson GH. Use of fludarabin in the treatment of acute myeloid leukemia. The Hematology Journal: The official journal of the European Haematology Association. 2004; 5(supp1): S62-S67.
7.
Webb DKH. Management of relapsed acute myeloid leukaemia. British Journal of Haematology. 1999; 106:851-9.
8.
Thomas X, Le QH. Treatment of acute myeloid leukemias in adults in relapse. Bulletin du Cancer 2002; 89(9):795-807.
9.
Soignet SL, Fankel SR, Douer D. A United States multicenter study of arsenic trioxide in relapsed APL. Journal of Clinical Oncology. 2001; 19(18): 3852-60.
10.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89(9): 3354-60.
11.
Perkins C, Kim CN , Fang G.Arsenic induces the apoptosis of multidrug –resistant human myeloid leukaemia cells that express bcr –abl or overexpress MDR, MRP, BCL, or BCL–XL. Blood 2000; 95: 1014-22.
12.
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. A United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukaemia. Blood. 1999; 94(suppl. 1): 698.
13.
Emadi A, Gore SD. Arsenic trioxide – An old drug rediscovered. Blood Rev. 2010 ; 24(4-5):191-9.
14.
Wang ZY, Chen Z. Acute promyelocytic leukaemia: from highly fatal to highly curable. Blood. 2008; 111(5):2505-15.
15.
Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukaemia, secondary leukemia and/or newly diagnosed patients who are at least 65 years old. Leukemia Research 2004;28(9): 909-19
16.
Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, et al. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukaemia Research 2002; 26(4): 391-98.
17.
Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, et al. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukaemia. Cancer 2008 ; 113 ( 9) :2504-11.
18.
Lee C, Lin Y, Huang M, Lin C, Liu C, Chow J ,et al. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukaemia acute myeloid leukaemia cells to arsenic trioxide in vivo, Leukaemia and Lymphoma 2006;47(3):521-29.
20.
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxideinduced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukaemia. Leukaemia: official journal of the Leukaemia Society of America. 2000;14(2):262- 70.
21.
Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O’Loughlin KL, et al. Arsenic trioxide affects signal transducers and the activators of transcription proteins through the alteration of protein tyrosine kinase phosphorylation. Clinical Cancer Research 2006 ;12(22): 6817-25.

DOI and Others

JCDR/2011/1673

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com